Shingles and Stress: Is There a Link? What the Research Says

The idea that stress can trigger shingles has moved well beyond folk wisdom. There's a plausible, well-documented immunological mechanism behind it and a growing body of epidemiological evidence supporting the association. Understanding this link matters not just for prevention but also for recognising when stress management is actually a clinical priority rather than a lifestyle suggestion.

Pearl Chemist Group offers shingles treatment through the NHS Pharmacy First programme. Find out more on our Pharmacy First page.

How Shingles Reactivation Actually Works

Shingles (herpes zoster) is caused by the varicella-zoster virus (VZV), the same virus responsible for chickenpox. After primary chickenpox infection, VZV retreats to the dorsal root ganglia along the spinal cord and the cranial nerve ganglia, where it establishes latency. It doesn't disappear; it simply sits dormant, held in check by VZV-specific cell-mediated immunity (CMI), primarily CD4+ and CD8+ T lymphocytes.

VZV reactivation occurs when this cellular immune surveillance falls below the threshold needed to keep the virus suppressed. Age is the most significant factor, as VZV-specific T-cell immunity declines measurably from around age 50 onwards. But immunological suppression can also be triggered acutely by illness, immunosuppressive medication, physical trauma, and, critically, psychological stress.

The Psychoneuroimmunology: Why Stress Suppresses VZV Immunity

The field of psychoneuroimmunology (PNI) has established robust connections between psychological states and immune function. The key pathway relevant to shingles involves the hypothalamic-pituitary-adrenal (HPA) axis and the sympathetic nervous system. Chronic psychological stress leads to sustained elevation of cortisol and catecholamines (adrenaline and noradrenaline), both of which have direct immunosuppressive effects.

Specifically, elevated cortisol suppresses the proliferation and cytotoxic activity of CD8+ T cells, the same cells responsible for monitoring and suppressing VZV in the ganglia. A 2012 meta-analysis in the Journal of Behavioural Medicine found that chronic stressors were significantly associated with reduced natural killer (NK) cell activity and impaired T-cell responses to viral antigens. VZV-specific T-cell responses fall into precisely this category.

Several prospective studies have also found elevated levels of inflammatory cytokines, particularly interleukin-6 (IL-6), in individuals with high chronic stress scores, which may further facilitate viral reactivation by promoting an inflammatory rather than antiviral immune environment.

What the Epidemiological Evidence Shows

The association between stressful life events and shingles onset has been documented across multiple studies. A 1998 study in the Journal of Psychosomatic Research found that adults who had experienced major stressful life events in the preceding six months had significantly higher rates of herpes zoster than matched controls. Divorce, bereavement, job loss, and serious illness in a family member were among the events associated with increased risk.

More recent research has examined chronic occupational stress, carer burden, and social isolation as potential drivers. The COVID-19 pandemic provided a large-scale inadvertent experiment: several studies published between 2021 and 2023 reported elevated shingles incidence in the general population during lockdown periods, with proposed mechanisms including the compounded effects of psychological stress, reduced social support, and disrupted sleep.

Shingles in Specific High-Risk Groups

The stress-shingles link is most clinically significant in populations where immunity is already compromised. People undergoing chemotherapy, those on long-term corticosteroids, organ transplant recipients, and people living with HIV are at substantially elevated risk of herpes zoster reactivation. In these groups, shingles can be more severe, more prolonged, and more likely to cause serious complications such as ophthalmic shingles (involving the eye) or post-herpetic neuralgia (PHN), a debilitating pain syndrome affecting the affected nerve territory that can persist for months or years after the rash resolves.

Post-Herpetic Neuralgia: The Complication Most People Don't Anticipate

The acute shingles rash typically resolves within two to four weeks. What many patients don't anticipate is that the nerve damage caused by viral replication in the ganglia can produce ongoing pain long after the skin has healed. Post-herpetic neuralgia affects roughly 10 to 15% of people with shingles and is significantly more common in those over 60 and those with more severe initial outbreaks.

PHN pain is neuropathic in character, described variously as burning, stabbing, electric, or allodynic (pain triggered by normally non-painful stimuli such as light touch or clothing). It is notoriously difficult to treat and can severely affect quality of life. This is one of the strongest arguments for early antiviral treatment and for proactive vaccination.

For access to shingles treatment, our NHS Pharmacy First service for shingles allows you to receive assessment and antiviral treatment at a Pearl Chemist Group branch without a GP appointment.

The Shingles Vaccine: Evidence for Efficacy

The Shingrix vaccine (recombinant zoster vaccine, adjuvanted) has transformed the shingles prevention landscape. Unlike the older Zostavax live vaccine, Shingrix is a non-live adjuvanted recombinant vaccine that produces robust and durable VZV-specific T-cell and antibody responses. Clinical trials (ZOE-50 and ZOE-70) demonstrated overall efficacy against shingles of approximately 97% in adults aged 50-69 and 91% in those aged 70 and over, with efficacy against PHN above 89% across all age groups. The vaccine requires two doses, given two to six months apart.

Speak to our pharmacy team about vaccination options. For supplementary immune support, explore our immunity supplements range.

Frequently Asked Questions

Can emotional trauma or grief trigger a shingles outbreak?

Yes. Acute psychological stressors, including bereavement, are among the documented triggers for shingles reactivation. The immunological mechanism is well characterised: acute grief triggers HPA axis activation, cortisol surges, and temporary impairment of cellular immunity, including VZV-specific T-cell function. If you develop shingles symptoms within weeks of a major psychological stressor, the timing may not be coincidental.

If I manage my stress better, does that reduce my shingles risk?

There's reasonable evidence that chronic stress management interventions, including mindfulness-based stress reduction (MBSR) and cognitive behavioural therapy (CBT), can improve cellular immune markers, including NK cell activity and T-cell responses. Whether this translates directly to measurable reductions in shingles incidence hasn't been robustly established in trials, but the mechanistic basis for the effect is plausible. Vaccination remains the most reliably evidence-based preventive intervention.

My shingles appeared on my face near my eye. Is this more serious?

Yes. Herpes zoster ophthalmicus (HZO), which affects the ophthalmic branch of the trigeminal nerve, requires urgent assessment by an ophthalmologist in addition to antiviral treatment. It can cause keratitis, uveitis, and, in rare cases, vision loss. If you develop a shingles rash on the forehead, the tip of the nose (Hutchinson's sign), or around the eye, seek emergency eye care.

Can you get shingles more than once?

Yes, though recurrence is uncommon in immunocompetent individuals. The risk of a second episode is estimated at around 1 to 6% over ten years in people with normal immune function. However, in immunocompromised individuals, recurrent shingles is significantly more common. Vaccination after a shingles episode is generally recommended to reduce the risk of recurrence.

What is the difference between shingles pain before and after the rash?

Pain preceding the rash (prodromal pain) results from VZV actively replicating in the sensory ganglia and travelling down nerve fibres, causing inflammation along the nerve pathway. Post-rash pain (post-herpetic neuralgia) results from structural nerve damage caused during the viral replication phase. The mechanisms are different, which is why antivirals are most useful when started early (reducing replication and nerve damage), while PHN typically requires neuropathic pain agents such as gabapentinoids or tricyclic antidepressants.